A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.

The serine/threonine Pim kinases are up-regulated in specific hematologic neoplasms, and play an important role in key signal transduction pathways, including those regulated by MYC, MYCN, FLT3-ITD, BCR-ABL, HOXA9, and EWS fusions. We demonstrate that SMI-4a, a novel benzylidene-thiazolidine-2, 4-dione small molecule inhibitor of the Pim kinases, kills a wide range of both myeloid and lymphoid cell lines with precursor T-cell lymphoblastic leukemia/lymphoma (pre-T-LBL/T-ALL) being highly sensitive. Incubation of pre-T-LBL cells with SMI-4a induced G1 phase cell-cycle arrest secondary to a dose-dependent induction of p27(Kip1), apoptosis through the mitochondrial pathway, and inhibition of the mammalian target of rapamycin C1 (mTORC1) pathway based on decreases in phospho-p70 S6K and phospho-4E-BP1, 2 substrates of this enzyme. In addition, treatment of these cells with SMI-4a was found to induce phosphorylation of extracellular signal-related kinase1/2 (ERK1/2), and the combination of SMI-4a and a mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor was highly synergistic in killing pre-T-LBL cells. In immunodeficient mice carrying subcutaneous pre-T-LBL tumors, treatment twice daily with SMI-4a caused a significant delay in the tumor growth without any change in the weight, blood counts, or chemistries. Our data suggest that inhibition of the Pim protein kinases may be developed as a therapeutic strategy for the treatment of pre-T-LBL.

[1]  Kyu-Tae Kim,et al.  Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.

[2]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[3]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[4]  Minjie Deng,et al.  TLR3 activation inhibits nasopharyngeal carcinoma metastasis via down-regulation of chemokine receptor CXCR4 , 2009, Cancer biology & therapy.

[5]  W. Gerald,et al.  Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. , 2008, The Journal of clinical investigation.

[6]  B. Blom,et al.  Pim1 Reconstitutes Thymus Cellularity in Interleukin 7–And Common γ Chain–Mutant Mice and Permits Thymocyte Maturation in Rag- but Not Cd3γ-Deficient Mice , 1999, The Journal of experimental medicine.

[7]  J. Barata,et al.  PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. , 2008, The Journal of clinical investigation.

[8]  P. Schwartzberg,et al.  Deficiency of PTEN in Jurkat T Cells Causes Constitutive Localization of Itk to the Plasma Membrane and Hyperresponsiveness to CD3 Stimulation , 2000, Molecular and Cellular Biology.

[9]  T. Tsuruo,et al.  Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. , 2008, Cancer research.

[10]  J. Tamburini,et al.  Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. , 2008, Blood.

[11]  L. Chodosh,et al.  The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. , 2003, Genes & development.

[12]  Jos Jonkers,et al.  Mice Deficient for All PIM Kinases Display Reduced Body Size and Impaired Responses to Hematopoietic Growth Factors , 2004, Molecular and Cellular Biology.

[13]  Linda N. Liu,et al.  Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. , 1999, Cancer research.

[14]  A. Berns,et al.  Proviral activation of the putative oncogene Pim‐1 in MuLV induced T‐cell lymphomas. , 1985, The EMBO journal.

[15]  R. Tchao,et al.  Role of biotransformation in 3-(3,5-dichlorophenyl)-2,4-thiazolidinedione-induced hepatotoxicity in Fischer 344 rats. , 2008, Toxicology.

[16]  M. Konopleva,et al.  Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins , 2002, Leukemia.

[17]  H. Bessler,et al.  Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma , 2004, Leukemia & lymphoma.

[18]  M. Raffeld,et al.  PTEN gene alterations in lymphoid neoplasms. , 1998, Blood.

[19]  A. Kraft,et al.  PIM1 Protein Kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells , 2009, Cancer biology & therapy.

[20]  A. Kraft,et al.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. , 2009, Journal of medicinal chemistry.

[21]  M. Salto‐Tellez,et al.  Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. , 2008, European journal of cancer.

[22]  M. Seto,et al.  Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5′-RACE and LA – PCR analyses of biopsy samples , 1999, Oncogene.

[23]  J. Tamburini,et al.  Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. , 2009, Blood.

[24]  A. Berns,et al.  Predisposition to lymphomagenesis in pim-1 transgenic mice: Cooperation with c-myc and N-myc in murine leukemia virus-induced tumors , 1989, Cell.

[25]  P. Pandolfi,et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. , 2008, The Journal of clinical investigation.

[26]  A Ma,et al.  E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice. , 1991, Oncogene.

[27]  Gouri Nanjangud,et al.  Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas , 2001, Nature.

[28]  A. Kraft,et al.  The PIM-2 Kinase Phosphorylates BAD on Serine 112 and Reverses BAD-induced Cell Death* , 2003, Journal of Biological Chemistry.

[29]  M. Cleary,et al.  Pim1 cooperates with E2a-Pbx1 to facilitate the progression of thymic lymphomas in transgenic mice , 1997, Oncogene.

[30]  S. Korsmeyer,et al.  Collaboration of pim-1 and bcl-2 in lymphomagenesis. , 1992, Current topics in microbiology and immunology.

[31]  B. Cheson,et al.  Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study , 2008, Leukemia & lymphoma.

[32]  Stefan Fröhling,et al.  Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. , 2007, Cancer cell.

[33]  F. Sigaux,et al.  The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Reeves,et al.  Pim-1 protein expression is regulated by its 5'-untranslated region and translation initiation factor elF-4E. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[35]  A. Berns,et al.  Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally , 1991, Molecular and cellular biology.

[36]  T. Wheeler,et al.  Growth and Survival Mechanisms Associated with Perineural Invasion in Prostate Cancer , 2004, Cancer Research.

[37]  A. Kraft,et al.  Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells , 2009, Molecular Cancer Therapeutics.

[38]  N Tsukada,et al.  Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. , 2000, Blood.

[39]  P. Laird,et al.  Pim-1 levels determine the size of early B lymphoid compartments in bone marrow , 1993, The Journal of experimental medicine.

[40]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[41]  G. Kroemer,et al.  Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. , 1997, Cancer research.

[42]  M. Nawijn,et al.  Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL. , 2006, Cancer research.

[43]  P. Meltzer,et al.  Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. , 2005, Blood.

[44]  P. Koskinen,et al.  Pim‐1 kinase promotes inactivation of the pro‐apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site , 2004, FEBS letters.

[45]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.

[46]  A. Berns,et al.  Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. , 1991, Cancer research.

[47]  S. Paternot,et al.  Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation. , 2009, Cancer research.